Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267003 | PMC |
| http://dx.doi.org/10.3389/fimmu.2025.1621252 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recipient-specific antibodies in HSCT: current knowledge and future perspectives.
Front Immunol
July 2025
Immunohematology and Transfusion Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Donor-derived anti-HLA antibodies in a haploidentical hematopoietic cell transplant recipient shortly after transplant.
Hum Immunol
July 2024
Departments of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. Electronic address:
A pediatric patient with acute myeloid leukemia was referred to our institution for investigational therapy after disease relapse following a mismatched unrelated donor hematopoietic cell transplant (HCT). Prior to second HCT, the patient's serum was negative for antibodies to class I and class II HLA. Eight days after receiving a maternal donor haploidentical transplant, the patient became platelet refractory and highly sensitized to multiple class I HLA.
View Article and Find Full Text PDFLow dose post-transplant cyclophosphamide and sirolimus induce mixed chimerism with CTLA4-Ig or lymphocyte depletion in an MHC-mismatched murine allotransplantation model.
Bone Marrow Transplant
May 2024
Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Allogeneic hematopoietic cell transplantation (allo-HCT) offers a curative option for patients with certain non-malignant hematological diseases. High-dose post-transplant cyclophosphamide (PT-Cy) (200 mg/kg) and sirolimus (3 mg/kg), (HiC) synergistically induce stable mixed chimerism. Further, sirolimus and cytotoxic T lymphocyte-associated antigen-4 immunoglobulin (CTLA4-Ig), also known as Abatacept (Aba), promote immune tolerance and allograft survival.
View Article and Find Full Text PDFIncidence and Role of Recipient-Specific Antibodies in Allogeneic Hematopoietic Cell Transplantation from Mismatched Related Donors.
Transplant Cell Ther
January 2024
Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland.
High titer of donor-specific antibodies (DSAs) increases the risk of graft rejection after mismatched related hematopoietic cell transplantation (HCT). There are no data regarding the incidence of anti-HLA recipient-specific antibodies (RSAs) and their role after transplantation. Here we aimed to identify the incidence of RSAs in a mismatched related hematopoietic cell donor population and their possible impact on immune-mediated complications, such as acute graft-versus-host disease (aGVHD), and complications resulting from endothelial injury, such as transplantation-associated thrombotic microangiopathy (TA-TMA) and veno-occlusive disease (VOD).
View Article and Find Full Text PDFMurine Models Provide New Insights Into Pathogenesis of Chronic Graft--Host Disease in Humans.
Front Immunol
December 2021
Riggs Institute, The Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, United States.
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for hematologic malignancies, but its success is complicated by graft--host disease (GVHD). GVHD can be divided into acute and chronic types. Acute GVHD represents an acute alloimmune inflammatory response initiated by donor T cells that recognize recipient alloantigens.
View Article and Find Full Text PDF